期刊文献+

二、三级公立医院实施国家基本药物制度存在的问题与对策 被引量:9

Problems and Countermeasures for the Use of Essential Drugs in Secondary and Tertiary Public Hospitals
原文传递
导出
摘要 目的:为提高二、三级公立医院基本药物使用比例提供参考。方法:调查基本药物在二、三级公立医院的使用现状,分析存在的问题,提出提高二、三级公立医院基本药物使用比例的建议。结果与结论:应打破公立医院的双向垄断地位、逐步转变公立医院和医务人员的收入结构,并借鉴国外经验,制定相应措施规范医师处方行为;充分发挥临床药师对处方的监督作用;对二、三级公立医院基本药物的使用比例给出明确的规定;同时应加大基本药物宣传,保障就医信息通畅,缓解医患信息不对称的状况。 OBJECTIVE: To provide reference for the extension of national essential drug system scope. METHODS: The use of essential drugs in public hospitals was briefly reviewed and the current problems of which were analyzed, then the corresponding recommendations to improve the essential drug use in secondary and tertiary public hospitals were put forward. RESULTS & CON- CLUSIONS : It is suggested to break the double monopoly position of public hospital, change the revenue structure of public hospi- tals and medical staff, refer to foreign experience and develop relevant measures to standardize prescribing behavior of pharma- cists; play the role of clinical pharmacist monitoring prescriptions; put forward clear specification for the use of essential drugs in secondary and tertiary public hospitals; at the same time, strengthen propaganda of essential drugs and guarantee unobstructed medi- cal information to alleviate the non-equivalent situation of doctor-patient information.
出处 《中国药房》 CAS CSCD 2012年第36期3364-3366,共3页 China Pharmacy
关键词 国家基本药物制度 基本药物 公立医院 问题 对策 National essential drug system Essential drugs Public hospitals Problem Countermeasures
  • 相关文献

参考文献8

  • 1卫生部.卫生部通报基本药物制度推进工作进展情况[EB/OL].2011-12-12.1attp://www.moh.gov.cn/publicfiles/business/htmlfiles/mohywzc/s7652/201110/53137.htm.
  • 2卫生部.医改进行时:基本药物走进大医嘲EB/0L].2011-06—10.http://www.moh.gov.cn/publicfiles/business/html—files/mohbgt/s6717/201106/51974.htm.
  • 3卫生部.陈竺:2011年卫生部门牵头的医改任务基本完成[EB/OL].2012—01—05.http://www.moh.gov.cn/public—files/business/htmlfiles/mohbgt/s3582/201201/53884.htm.
  • 4朱恒鹏.医院是如何同政府博弈的[N].21世纪经济报,2011-05-13.
  • 5罗文华,阮景,邱家学,李翔.药学服务诚信缺失的经济学分析及对策[J].中国药房,2005,16(4):248-250. 被引量:4
  • 6国务院.关于印发"十二五"期间深化医药卫生体制改革规划暨实施方案的通知[z].2012.
  • 7黄姝颖,沈春明.论我国临床药师处方权的内容及其实现[J].中国药房,2011,22(34):3243-3246. 被引量:8
  • 8刘玉聪,孙利华,孙倩.国外规范医生处方行为的措施及其对我国的启示[J].中国药业,2010,19(24):9-10. 被引量:6

二级参考文献24

  • 1董文勇.德国社会医疗保险用药费用控制制度及其对中国的启示[J].环球法律评论,2006,28(2):208-217. 被引量:24
  • 2R.Fijn,L T.W.de Jang-van den Berg,J.R.B.J.Brouwers,Rational pharmacotherapy in The Netherlands:formulary management in Dutch hospitals[J].Pharm World Sci,1999,21(2).75-76.
  • 3Azeem Majeed,Norman Evans,Panla Head.What can PACT tell us about prescribing in general practice?[J].BMJ,1997(315):1 515-1 519.
  • 4Jacobzone S.Pharmaceutical policies in OECD countries:Reconciling social and industrial goals[R].OECD Labour Market and Social Policy Occasional Papers,2000(40):45.
  • 5Heidrun B.Sturm.Influencing physician prescribing in an international context:the role of systems,policies and patients[D].Groningen:Rijksuniversiteit Groningen,2007:136.
  • 6Silvia M.Ess,Sebastian Sehneeweiss,Thomas D.Szucs.European healthcare policies for controlling drug expenditure[J].Pharmaeoeeonomies,2003,21(2):89-103.
  • 7Sehulenburg JM,Uber A.Current issues in German healthcare[J].Pharmacoeconoroics,1997,12(5):517-523.
  • 8Hans V,Hogerzeil.Promoting rational prescribing:an international perspective[J].BrJ elin Pharmac,1995,(39):3.
  • 9Pharmacy Benefit Management Savings or Shackles? Healtheare Business Digest Online[EB/OL1.http://www,mmhc.eom/hcbk/articles/hebd9803/pharmacy.Html.2002.
  • 10Tully MP, Latif S, Cantrill JA, et al.Pharmacists' changing views of their supplementary prescribing authority[J]. Pharm World Sci , 2007,29(6) : 628.

共引文献16

同被引文献111

  • 1刘有贵,蒋年云.委托代理理论述评[J].学术界,2006(1):69-78. 被引量:214
  • 2朱航宇.信息不对称条件下的药品价格管理[J].价格理论与实践,2006(5):37-38. 被引量:9
  • 3吴建文,沈莉,乔延清.药价虚高博弈分析[J].中国工业经济,2006(7):80-85. 被引量:21
  • 4曼昆.经济学原理:微观经济学分册[M].5版.梁小民,梁砾,译.北京:北京大学出版社,2009.
  • 5朱强,蔡蓉华,何峻主编.中文核心期刊要目总览2011年版.北京:北京大学出版社,2011.
  • 6安徽省卫生厅.关于做好二甲以上医疗机构优先配备使用基本药物工作的通知[Z],卫药秘[2011]806号.
  • 7Hu S. Essential medicine policy in China: pros and cons. Journal of Medical Economics, 2012, 16(2): 289-294.
  • 8Li Y, Ying C, Sufang G, et al. Evaluation, in three provinces, of the introduction and impact of China’s National Essential Medicines Scheme. Bull World Health Organ, 2013, 91(3): 184-194.
  • 9Barber SL, Huang B, Santoso B, et al. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. Journal of Global Health, 2013, 3(1): 010303.
  • 10国务院. 国务院关于印发 “十二五” 期间深化医药卫生体制改革规划暨实施方案的通知. 2012.

引证文献9

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部